- Report
- November 2025
- 150 Pages
China
From €4349EUR$4,850USD£3,716GBP
- Report
- April 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- April 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- March 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- March 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- June 2024
- 123 Pages
Asia Pacific
From €1345EUR$1,500USD£1,149GBP
- Report
- March 2025
- 114 Pages
Global
From €3500EUR$4,182USD£3,095GBP
- Report
- October 2025
- 87 Pages
Saudi Arabia
From €4035EUR$4,500USD£3,447GBP
- Report
- March 2025
- 130 Pages
Global
From €4349EUR$4,850USD£3,716GBP
- Report
- August 2024
Global
From €2197EUR$2,450USD£1,877GBP
- Drug Pipelines
- July 2023
- 139 Pages
Global
From €13445EUR$14,995USD£11,488GBP
- Report
- June 2023
- 91 Pages
Global
From €3500EUR$4,182USD£3,095GBP
The Neuroprotective market is a subset of Central Nervous System (CNS) drugs that are designed to protect the brain and spinal cord from damage caused by disease, trauma, or other conditions. Neuroprotective drugs are used to treat a variety of neurological disorders, including stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. These drugs can also be used to reduce the risk of developing these conditions. Neuroprotective drugs work by reducing inflammation, improving blood flow, and protecting neurons from damage.
Neuroprotective drugs are an important part of treating neurological disorders, as they can help reduce the severity of symptoms and improve quality of life. They are also used to prevent further damage to the brain and spinal cord.
Some companies in the Neuroprotective market include AbbVie, AstraZeneca, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more
